Loading
A phase 2/3 trial in lung cancer, run by Swiss Cancer Institute, now recruiting.
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2/3, randomised interventional study registered as NCT07149649 by Swiss Cancer Institute, with a registry enrolment figure of 230 participants, started 2026-08 and due to reach its primary completion in 2031-01-01. Interventions recorded: Magnesiocard; Magnesium Diasporal; Microcrystalline cellulose; Isotonic saline solution 0.9%. Conditions listed: Metastatic NSCLC - Non-Small Cell Lung Cancer. Primary outcome: Primary endpoint of Phase II part: Progression-free survival (PFS); Primary endpoint of Phase III part: Overall survival (OS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of NSCLC (adeno-, squamous-, large cell carcinoma or NSCLC not otherwise specified);". Sites: Switzerland. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.